INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Against Veru Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Veru Inc. (“Veru” or “the Company”) (NASDAQ: VERU) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Veru suffered a 51% drop in share price value in intraday trading on November 10, 2022, after an FDA Advisory Committee voted against recommending an EUA for its COVID-19 pill VERU-111.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Veru Stock currently trades with a raise of +16,61 % to 7,195EUR on the Tradegate stock exchange.
|Diskussion: Veru Inc. - Entwicklung neuartiger Medikamente zur Behandlung von Prostatakrebs und Brustkrebs|